Skip to content
Exits and Outcomes
Become A Subscriber
Digital health research, news, and analysis from Brian Dolan.
consider an Enterprise subscription
2 of 8
Pharma execs talk digital therapeutic pricing. Germany reimburses first two prescribable apps.
Proteus founders explain. Investors talk DTx.
Apple eyes asthma, sleep apnea SaMDs? Amwell-Teladongo suit.
32 Pear patents. Amwell $644M IPO.
New Teladongo merger details. Pear’s acquisitive study strategy.
Will Amazon ruin voice biomarkers? Amwell S-1 insights.
20 percent of Rx-only digital therapeutics have studies so far.
Nine thoughts on Teladongo. CPT sneak peek.
Hinge plans virtual MSK clinic. Livongo upping focus on DPP?
Livongo’s IPO anniversary. DTx pipelines.
1 of 8